Larimar Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2019
Filed with the SEC on Aug 8, 2019 and accepted by EDGAR at Aug 8, 2019, 17:10 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-04-01 to 2019-06-30 | $0 | us-gaap:Revenues |
| Revenue | 6 months2019-01-01 to 2019-06-30 | $0 | us-gaap:Revenues |
| Research and development | 3 months2019-04-01 to 2019-06-30 | $8.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2019-01-01 to 2019-06-30 | $18.2m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2019-04-01 to 2019-06-30 | −$12.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2019-01-01 to 2019-06-30 | −$25.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2019-04-01 to 2019-06-30 | $478.0k | us-gaap:InterestExpense |
| Interest expense | 6 months2019-01-01 to 2019-06-30 | $978.0k | us-gaap:InterestExpense |
| Net income | 3 months2019-04-01 to 2019-06-30 | −$12.1m | us-gaap:NetIncomeLoss |
| Net income | 6 months2019-01-01 to 2019-06-30 | −$25.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-04-01 to 2019-06-30 | −$0.32 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2019-01-01 to 2019-06-30 | −$0.68 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months2019-01-01 to 2019-06-30 | −$23.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2019-01-01 to 2019-06-30 | $409.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-06-30 | $37.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-06-30 | $94.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-06-30 | $103.9m | us-gaap:Assets |
| Current liabilities | At period end2019-06-30 | $13.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-06-30 | $31.7m | us-gaap:Liabilities |
| Long-term debt | At period end2019-06-30 | $18.2m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2019-06-30 | $72.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-19-030904. Last ingested by Listed: Nov 13, 2026, 17:49 ET. Listed shows no prices and gives no investment advice.